These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 22841970)

  • 1. Process of care for hepatitis C infection is linked to treatment outcome and virologic response.
    Kanwal F; Hoang T; Chrusciel T; Kramer JR; El-Serag HB; Dominitz JA; Asch SM
    Clin Gastroenterol Hepatol; 2012 Nov; 10(11):1270-1277.e3. PubMed ID: 22841970
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of addition of statins to antiviral therapy in hepatitis C virus-infected persons: Results from ERCHIVES.
    Butt AA; Yan P; Bonilla H; Abou-Samra AB; Shaikh OS; Simon TG; Chung RT; Rogal SS;
    Hepatology; 2015 Aug; 62(2):365-74. PubMed ID: 25847403
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association between facility characteristics and the process of care delivered to patients with hepatitis C virus infection.
    Kanwal F; Hoang T; Chrusciel T; Kramer JR; El-Serag HB; Durfee J; Dominitz JA; Yano EM; Asch SM
    Dig Dis Sci; 2014 Feb; 59(2):273-81. PubMed ID: 23934366
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sustained Virologic Response to a Dual Peginterferon alfa-2a and Ribavirin in Treating Chronic hepatitis C Infection: A Retrospective Cohort Study.
    Naing C; Sitt T; Aung AT; Aung K
    Medicine (Baltimore); 2015 Jul; 94(30):e1234. PubMed ID: 26222859
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A sustained virologic response reduces risk of all-cause mortality in patients with hepatitis C.
    Backus LI; Boothroyd DB; Phillips BR; Belperio P; Halloran J; Mole LA
    Clin Gastroenterol Hepatol; 2011 Jun; 9(6):509-516.e1. PubMed ID: 21397729
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of sustained virological response on the risk of extrahepatic manifestations of hepatitis C virus infection.
    Mahale P; Engels EA; Li R; Torres HA; Hwang LY; Brown EL; Kramer JR
    Gut; 2018 Mar; 67(3):553-561. PubMed ID: 28634198
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sustained virologic response with 6 weeks or less of direct-acting antiviral therapy for chronic hepatitis C: Experience at a veterans affairs healthcare system.
    Joshi P; Atherton A
    J Gastroenterol Hepatol; 2019 Dec; 34(12):2173-2178. PubMed ID: 31062412
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-world effectiveness of daclatasvir plus sofosbuvir and velpatasvir/sofosbuvir in hepatitis C genotype 2 and 3.
    Belperio PS; Shahoumian TA; Loomis TP; Mole LA; Backus LI
    J Hepatol; 2019 Jan; 70(1):15-23. PubMed ID: 30266283
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Is response guided therapy dead? Low cure rates in patients with detectable hepatitis C virus at week 4 of treatment.
    Thornton K; Deming P; Manch RA; Moore A; Kohli A; Gish R; Sussman NL; Khaderi S; Scott J; Mera J; Box T; Qualls C; Sedillo M; Arora S
    Hepatol Int; 2016 Jul; 10(4):624-31. PubMed ID: 27098355
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Peginterferon alfa and ribavirin for chronic hepatitis C in patients eligible for shortened treatment, re-treatment or in HCV/HIV co-infection: a systematic review and economic evaluation.
    Hartwell D; Jones J; Baxter L; Shepherd J
    Health Technol Assess; 2011 Apr; 15(17):i-xii, 1-210. PubMed ID: 21473834
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-world experiences with direct-acting antiviral agents for chronic hepatitis C treatment.
    Daniel KE; Saeian K; Rizvi S
    J Viral Hepat; 2020 Feb; 27(2):195-204. PubMed ID: 31602715
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Significance of day-1 viral response of hepatitis C virus in patients with chronic hepatitis C receiving direct-acting antiviral therapy.
    Toyoda H; Kumada T; Tada T; Yama T; Mizuno K
    J Gastroenterol Hepatol; 2018 Jun; 33(6):1264-1270. PubMed ID: 29164675
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Platelet count is associated with sustained virological response rates in treatments for chronic hepatitis C.
    Jun BG; Park EJ; Lee WC; Jang JY; Jeong SW; Kim YD; Cheon GJ; Cho YS; Lee SH; Kim HS; Lee YN; Kim SG; Kim YS; Kim BS
    Korean J Intern Med; 2019 Sep; 34(5):989-997. PubMed ID: 29529840
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early View of the Effectiveness of New Direct-Acting Antiviral (DAA) Regimens in Patients with Hepatitis C Virus (HCV).
    Walker DR; Pedrosa MC; Manthena SR; Patel N; Marx SE
    Adv Ther; 2015 Nov; 32(11):1117-27. PubMed ID: 26538232
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Eltrombopag increases platelet numbers in thrombocytopenic patients with HCV infection and cirrhosis, allowing for effective antiviral therapy.
    Afdhal NH; Dusheiko GM; Giannini EG; Chen PJ; Han KH; Mohsin A; Rodriguez-Torres M; Rugina S; Bakulin I; Lawitz E; Shiffman ML; Tayyab GU; Poordad F; Kamel YM; Brainsky A; Geib J; Vasey SY; Patwardhan R; Campbell FM; Theodore D
    Gastroenterology; 2014 Feb; 146(2):442-52.e1. PubMed ID: 24126097
    [TBL] [Abstract][Full Text] [Related]  

  • 16. IL28B and interferon-gamma inducible protein 10 for prediction of rapid virologic response and sustained virologic response in HIV-HCV-coinfected patients.
    Payer BA; Reiberger T; Aberle J; Ferenci P; Holzmann H; Rieger A; Peck-Radosavljevic M;
    Eur J Clin Invest; 2012 Jun; 42(6):599-606. PubMed ID: 22117591
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Real-world medical costs of antiviral therapy among patients with chronic HCV infection and advanced hepatic fibrosis.
    Maan R; Zaim R; van der Meer AJ; Feld JJ; Wedemeyer H; Dufour JF; Lammert F; Manns MP; Zeuzem S; Hansen BE; Janssen H; Veldt BJ; de Knegt RJ; Uyl-de Groot CA
    J Gastroenterol Hepatol; 2016 Nov; 31(11):1851-1859. PubMed ID: 26990109
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The performance of process measures in hepatitis C.
    Kanwal F; Hoang T; Kramer J; Chrusciel T; El-Serag H; Dominitz JA; Asch SM
    Am J Gastroenterol; 2012 Oct; 107(10):1512-21. PubMed ID: 22777337
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Direct-acting antiviral treatment of chronic HCV-infected patients on opioid substitution therapy: Still a concern in clinical practice?
    Christensen S; Buggisch P; Mauss S; Böker KHW; Schott E; Klinker H; Zimmermann T; Weber B; Reimer J; Serfert Y; Wedemeyer H
    Addiction; 2018 May; 113(5):868-882. PubMed ID: 29359361
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Integrated treatment of hepatitis C virus infection among people who inject drugs: A multicenter randomized controlled trial (INTRO-HCV).
    Fadnes LT; Aas CF; Vold JH; Leiva RA; Ohldieck C; Chalabianloo F; Skurtveit S; Lygren OJ; Dalgård O; Vickerman P; Midgard H; Løberg EM; Johansson KA;
    PLoS Med; 2021 Jun; 18(6):e1003653. PubMed ID: 34061883
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.